Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi®, a biosimilar referencing Humira® 1 (adalimumab), for th ...

Sieborg J, Thein D, Maul J-T, et al. Drug survival of patients with psoriasis, who underwent a non-medical mandatory switch from adalimumab originator to either of the two biosimilar biologics ...

METHODOLOGY: Researchers conducted a cohort study using data on patients with psoriasis who were treated with adalimumab, a tumor necrosis factor alpha inhibitor used to treat moderate to severe ...

Adalimumab Versus Biosimilars for Psoriasis – An American Academy of Dermatology Association Reading Room selection July 18, 2025 • 1 min read ...

June 23 (Reuters) - Biogen Inc * Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by committee for medicinal products for human use ...